Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA says biopsy needle too large for lumpectomy:

This article was originally published in Clinica

Executive Summary

An FDA advisory panel said last week that there is no scientific evidence to suggest that two devices used for breast biopsies should also be marketed for lumpectomy. The two devices, US Surgical's ABBI and Biopsys Medical Mammotome, use larger needles than other biopsy devices, and thus take more tissue. In June, the FDA issued a warning letter to US Surgical to stop marketing its device for lumpectomy. The General and Plastic Surgery Devices panel also said the agency should restrict the product's use in breast biopsies in those cases that are difficult to diagnose.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT089628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel